Development of RGD-based radiotracers for tumor imaging and therapy: Translating from bench to bedside

Current Molecular Medicine

Volumn 13, Issue 10, 2013, Pages 1487-1505

  Liu, Z ^a,b   Wang, F ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Arg Gly Asp (RGD); Integrin v 3; Molecular imaging; Radionuclide therapy; Radiotracer; Tumor

Indexed keywords

99MTC 3PRGD2; ARGINYLGLYCYLASPARTIC ACID; BOMBESIN; DASATINIB; DIMER; FIBRINOGEN; FIBRONECTIN; FLUCICLATIDE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GASTRIN RELEASING PEPTIDE RECEPTOR; HETERODIMER; LIGAND; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1, 2, 3 TRIAZOL 1 YL) ETHOXY] 4 QUINAZOLINAMINE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PACLITAXEL; RADIOISOTOPE; SUNITINIB; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; YTTRIUM 90;

ANGIOGENESIS; BINDING AFFINITY; CANCER INHIBITION; CANCER SCREENING; CANCER THERAPY; CHEMICAL STRUCTURE; GATED SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; LOW DRUG DOSE; MOLECULAR IMAGING; MULTICENTER STUDY (TOPIC); NEOPLASM; NONHUMAN; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN MULTIMERIZATION; RADIOACTIVITY; REVIEW; SINGLE DRUG DOSE;

ANIMALS; HUMANS; NEOPLASMS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY, IMAGE-GUIDED; SURGERY, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84889053462     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524013666131111115347     Document Type: Review

References (107)

1. Mallidi S, Luke GP, Emelianov S. Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance. Trends Biotechnol 2011; 29: 213-21.
2. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001; 219: 316-33.
3. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-80.
4. Cai W, Gambhir SS, Chen X. Chapter 7. Molecular imaging of tumor vasculature. Methods Enzymol 2008; 445: 141-76.
5. Cai W, Niu G, Chen X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 2008; 14: 2943-73.
6. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 683-93.
7. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
9. Sharma RA, Harris AL, Dalgleish AG, Steward WP, O'Byrne KJ. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol 2001; 2: 726-32.
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
11. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673.
12. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nature reviews Cancer 2002; 2: 91.
13. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin v 3 for angiogenesis. Science 1994; 264: 569-71.
14. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227-30.
15. Liu Z, Wang F, Chen X. Integrin v 3-targeted cancer therapy. Drug Development Research 2008; 69: 329-39.
16. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin v 3 targeted radiotracers for tumor imaging. Mol Pharm 2006; 3: 472-87.
17. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci 2009; 14: 887-99.
18. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 2008; 27: 631-44.
19. Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006; 33: 54-63.
20. Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 2009; 42: 969-80.
21. Sutcliffe-Goulden JL, O'Doherty MJ, Marsden PK, Hart IR, Marshall JF, Bansal SS. Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging 2002; 29: 754-9.
22. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991; 291: 50-4.
23. Fani M, Psimadas D, Zikos C, et al. Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer Res 2006; 26: 431-4.
24. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61: 1781-5.
25. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated v 3 integrin in cancer patients by positron emission tomography and 18F-Galacto-RGD. PLoS Med 2005; 2: e70.
26. Liu S, Hsieh WY, Kim YS, Mohammed SI. Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjug Chem 2005; 16: 1580-8.
27. Jia B, Shi J, Yang Z, et al. 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin v 3 expression. Bioconjug Chem 2006; 17: 1069-76.
28. Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X. Small-animal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009; 50: 1168-77.
29. Dijkgraaf I, Kruijtzer JA, Liu S, et al. Improved targeting of the v 3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 2007; 34: 267-73.
30. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002; 17: 641-6.
31. Wu Y, Zhang X, Xiong Z, et al. microPET imaging of glioma integrin v 3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005; 46: 1707-18.
32. Li ZB, Chen K, Chen X. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin v 3 expression. Eur J Nucl Med Mol Imaging 2008; 35: 1100-8.
33. Capello A, Krenning EP, Bernard BF, Breeman WA, Erion JL, de Jong M. Anticancer activity of targeted proapoptotic peptides. J Nucl Med 2006; 47: 122-9.
34. Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen MP, de Jong M. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 2004; 45: 1716-20.
35. Bernard B, Capello A, van Hagen M, et al. Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm 2004; 19: 173-80.
36. Liu Z, Yan Y, Chin FT, Wang F, Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 2009; 52: 425-32.
37. Li ZB, Wu Z, Chen K, Ryu EK, Chen X. 18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging. J Nucl Med 2008; 49: 453-61.
38. Liu Z, Niu G, Wang F, Chen X. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009; 36: 1483-94.
39. Liu S. Radiolabeled cyclic RGD peptides as integrin v 3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009; 20: 2199-213.
40. Walsh S, Shah A, Mond J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 2003; 47: 554-8.
41. Chen X, Hou Y, Tohme M, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor v 3-integrin expression. J Nucl Med 2004; 45: 1776-83.
42. Chen X, Park R, Hou Y, et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004; 31: 1081-9.
43. Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004; 31: 11-9.
44. Liu Z, Niu G, Shi J, et al. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin v 3 PET imaging. Eur J Nucl Med Mol Imaging 2009; 36: 947-57.
45. Wang L, Shi J, Kim YS, et al. Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm 2009; 6: 231-45.
46. 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem 2008; 51: 7980-90.
47. Shi J, Wang L, Kim YS, et al. 99mTcO(MAG2-3G3-dimer): a new integrin v 3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging 2009; 36: 1874-84.
48. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S. Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem 2009; 20: 750-9.
49. Shi J, Kim YS, Chakraborty S, Jia B, Wang F, Liu S. 2-Mercaptoacetylglycylglycyl (MAG2) as a Bifunctional Chelator for 99mTc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics. Bioconjug Chem 2009; 20: 1559-68.
50. Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers. Eur J Nucl Med Mol Imaging 2009; 36: 1296-307.
51. Franc BL, Acton PD, Mari C, Hasegawa BH. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med 2008; 49: 1651-63.
52. Jia B, Liu Z, Zhu Z, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin alphavbeta3-selective radiotracer 99mTc-3PRGD2 in non-human primates. Mol Imaging Biol 2011; 13: 730-6.
53. Hohne A, Mu L, Honer M, et al. Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem 2008; 19: 1871-9.
54. Hohne A, Yu L, Mu L, et al. Organofluorosilanes as model compounds for 18F-labeled silicon-based PET tracers and their hydrolytic stability: experimental data and theoretical calculations (PET = positron emission tomography). Chemistry 2009; 15: 3736-43.
55. Ting R, Harwig C, Aufdem Keller U, et al. Toward [18F]-labeled aryltrifluoroborate radiotracers: in vivo positron emission tomography imaging of stable aryltrifluoroborate clearance in mice. J Am Chem Soc 2008; 130: 12045-55.
56. McBride WJ, Sharkey RM, Karacay H, et al. A novel method of 18F radiolabeling for PET. J Nucl Med 2009; 50: 991-8.
57. McBride WJ, D'Souza CA, Sharkey RM, et al. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem 2010; 21: 1331-40.
58. Laverman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with 18F-fluorine. J Nucl Med 2010; 51: 454-61.
59. Liu S, Liu H, Jiang H, Xu Y, Zhang H, Cheng Z. One-step radiosynthesis of 18F-AlF-NOTA-RGD for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging 2011; 38: 1732-41.
60. Chin FT, Shen B, Liu S, et al. First experience with clinical-grade 18F-FPP(RGD)2: an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol 2012; 14: 88-95.
61. Lang L, Li W, Guo N, et al. Comparison study of 18F-FAl-NOTA-PRGD2, 18F-FPPRGD2, and 68Ga-Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem 2011; 22: 2415-22.
62. Jeong JM, Hong MK, Chang YS, et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008; 49: 830-6.
63. Decristoforo C, Hernandez Gonzalez I, Carlsen J, et al. 68Ga-and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008; 35: 1507-15.
64. Liu Z, Yan Y, Liu S, Wang F, Chen X. 18F, 64Cu, and 68Ga Labeled RGD-Bombesin Heterodimeric Peptides for PET Imaging of Breast Cancer. Bioconjugate Chem 2009; 20: 1016-25.
65. Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005; 46: 1333-41.
66. Beer AJ, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006; 47: 763-9.
67. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using 18F-Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006; 12: 3942-9.
68. Beer AJ, Grosu AL, Carlsen J, et al. 18F-galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 6610-6.
69. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008; 49: 255-9.
70. Beer AJ, Lorenzen S, Metz S, et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 2008; 49: 22-9.
71. Jeswani T, Padhani AR. Imaging tumour angiogenesis. Cancer Imaging 2005; 5: 131-8.
72. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET Imaging of Integrin alphaVbeta3 Expression. Theranostics 2011; 1: 48-57.
73. Metz S, Ganter C, Lorenzen S, et al. Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med 2010; 51: 1691-8.
74. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 1995; 13: 265-70.
75. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008; 49: 879-86.
76. McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med 2008; 49: 1664-7.
77. Liu S, Liu Z, Chen K, et al. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of alphavbeta3 integrin expression. Mol Imaging Biol 2010; 12: 530-8.
78. Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging alpha(v)beta(3) integrin levels. Radiology 2011; 260: 182-91.
79. Doss M, Kolb HC, Zhang JJ, et al. Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans. J Nucl Med 2012; 53: 787-95.
80. Kim JH, Lee JS, Kang KW, et al. Whole-body distribution and radiation dosimetry of 68Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Cancer Biother Radiopharm 2012; 27: 65-71.
81. Sivolapenko GB, Skarlos D, Pectasides D, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998; 25: 1383-9.
82. Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006; 47: 1434-9.
83. Bach-Gansmo T, Bogsrud TV, Skretting A. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and 99mTc-labelled NC100692. Clin Physiol Funct Imaging 2008; 28: 235-9.
84. Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study. J Nucl Med 2012; 53: 716-22.
85. Ma Q, Ji B, Jia B, et al. Differential diagnosis of solitary pulmonary nodules using 99mTc-3P-RGD scintigraphy. Eur J Nucl Med Mol Imaging 2011; 38: 2145-52.
86. Jung KH, Lee KH, Paik JY, et al. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med 2006; 47: 2000-7.
87. Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 2009; 50: 116-22.
88. Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled alphaVbeta3-integrin and alphaV beta5-integrin imaging agent. J Nucl Med 2011; 52: 424-30.
89. Dumont RA, Hildebrandt I, Su H, et al. Noninvasive imaging of alphavbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res 2009; 69: 3173-9.
90. Sun X, Yan Y, Liu S, et al. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 2011; 52: 140-6.
91. Yang M, Gao H, Sun X, et al. Multiplexed PET probes for imaging breast cancer early response to VEGF/rGel treatment. Mol Pharm 2011; 8: 621-8.
92. Yang M, Gao H, Yan Y, et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging 2011; 38: 1237-47.
93. Sprague JE, Kitaura H, Zou W, et al. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J Nucl Med 2007; 48: 311-8.
94. Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ. Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases. J Nucl Med 2009; 50: 1873-80.
95. Hua J, Dobrucki LW, Sadeghi MM, et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation 2005; 111: 3255-60.
96. Dimastromatteo J, Riou LM, Ahmadi M, et al. In vivo molecular imaging of myocardial angiogenesis using the alphav beta3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol 2010; 17: 435-43.
97. Sherif HM, Saraste A, Nekolla SG, et al. Molecular imaging of early alphavbeta3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med 2012; 53: 318-23.
98. Gao H, Lang L, Guo N, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging 2012; 39: 683-92.
99. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alphav beta3 integrin binding peptides in a nude mouse model. Cancer Res 2002; 62: 6146-51.
100. Janssen M, Frielink C, Dijkgraaf I, et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm 2004; 19: 399-404.
101. Yoshimoto M, Ogawa K, Washiyama K, et al. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int J Cancer 2008; 123: 709-15.
102. Liu Z, Shi J, Jia B, et al. Two 90Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol Pharm 2011; 8: 591-9.
103. Pool SE, Krenning EP, Koning GA, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 2010; 40: 209-18.
104. Slomka PJ, Patton JA, Berman DS, Germano G. Advances in technical aspects of myocardial perfusion SPECT imaging. J Nucl Cardiol 2009; 16: 255-76.
105. Gambhir SS, Berman DS, Ziffer J, et al. A novel high-sensitivity rapid-acquisition single-photon cardiac imaging camera. J Nucl Med 2009; 50: 635-43.
106. Nakazato R, Tamarappoo BK, Kang X, et al. Quantitative upright-supine high-speed SPECT myocardial perfusion imaging for detection of coronary artery disease: correlation with invasive coronary angiography. J Nucl Med 2010; 51: 1724-31.
107. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alphavbeta3 expression in patients with malignant glioma by 18F-Galacto-RGD positron emission tomography. Neuro Oncol 2009; 11: 861-70.